In the Phase 1/1b study, sitravatinib was evaluated in patients with metastatic CRPC based on the key roles of MET and VEGFR2 in prostate cancer progression, with high expression levels of both RTKs being associated with aggressive disease [17]. This evidence concerns the gene MET and prostate cancer.